Drug Targets – Products
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring
Bio-Rad Laboratories, Inc. today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin, secukinumab and the secukinumab–interleukin 17A drug-target complex.
Ubiquigent Appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board
Ubiquigent Limited has announced the expansion of its Scientific Advisory Board with the appointments of Professor Helen Walden and Professor John Davis.
Orbit Discovery Awarded Innovate UK Grant To Expand High Throughput Cell-Based Functional Screening Platform Capabilities
Orbit Discovery Ltd. has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.
Dolomite Bio Releases Hydrogel Reagent Kits for Agarose Encapsulation and 3D Cell Culture Research
Dolomite Bio launches new hydrogel-focused reagent kits, enabling high-throughput encapsulation of cells in hydrogel scaffolds.
Proteros Expands Oncology Collaboration and License Agreement With AstraZeneca
Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties.
NanoTemper Technologies Launches Spectral Shift
NanoTemper Technologies has announced the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery.
Agilent Announces the Innovative Seahorse XF Pro Analyzer
Agilent Technologies Inc. has announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.
Research Tools for Anti-Cancer Drug Targets
Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.
SomaScan Assay: The World's Largest Proteomic Platform
Discover more with the first and only technology that can measure 7,000 proteins over a broad range of concentrations. Built on 20 years of pioneering proteomics technology, The SomaScan Assay enables unprecedented biomarker and drug discovery and now, you can seamlessly transition from discovery to validation with new SomaScan panels and SomaSignal TM Tests bolstering the entire drug discovery and development pipeline, all via a straightforward fee-for-service model.
Synthetic Immune Recruitment – A New Way To Fight Tumors
The utility and efficiency of the Octet® platform at characterizing covalent immune recruiter molecule function and their efficacy as modulators of protein proximity was demonstrated. Efficient in vitro validation further enables the potential acceleration of CIR translation to in vivo model validation and the clinic as a new class of synthetic tumor immunotherapeutic.